Ascend Advanced Therapies, a total solutions gene therapy development partner, has acquired the CMC team and site in Alachua, Florida from Beacon Therapeutics.
The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities and additional experts to the Ascend team.
It also includes a long-term partnership with Beacon to continue manufacturing its products for clinical and commercial use, securing product supply for Beacon and enabling it to focus on clinical development.
“Ascend was founded with a unique science and technology-driven strategy. As we continue building the most flexible adeno-associated virus (AAV) platform across serotypes on the market, we also understand the critical value of our highly experienced employees,” Mike Stella, CEO at Ascend stated.
“This acquisition allows us to now support customers from research through to commercialisation and adds to one of the most experienced gene therapy teams in the market. Every day we are working together to grow the company with a long-term mindset of quality first to appropriately balance quality and yield for the life of each product.”
“We are excited to enter this strategic arrangement with Ascend to advance our sight saving therapies toward approval. This alignment is critical to securing GMP drug product supply for our late-stage clinical asset AGTC-501 for the treatment of X-linked retinitis pigmentosa,” said David Fellows, CEO at Beacon Therapeutics.
The Beacon Therapeutics portfolio currently includes three ocular gene therapy products utilizing AAV to deliver gene constructs that address retinal disorders. The proteins expressed from the transduced constructs compensate for deficiencies in the patient cells, or otherwise intervene in pathological processes, potentially restoring vision or preventing disease progression.
